Older Age Associated With Better Post-Transplant Survival in Newly Diagnosed AML

Originally published by our sister publication Specialty Pharmacy ContinuumBy Fran KritzOlder age was independently associated with better post-transplant survival in newly diagnosed acute myeloid leukemia (AML) patients receiving venetoclax (Venclexta, AbbVie/Genentech) and a hypomethylating agent (HMA) (Ven-HMA), according to a presentation at the 2026 ASCO Annual Meeting, in Chicago (abstract 6530). Of note, survival was not associated with genetic profile at the time of allogeneic stem cell